Citations

Clear

1446 citation(s) found for "Howard, F".

CAN-2409 plus prodrug with standard of care immune checkpoint inhibitor for patients with stage III/IV NSCLC.
Maldonado, Fabien , Reisenauer, Janani , Swan, Randy, Caine, Audra, Lopez, Lenika, Manzanera, Andrea G., Nichols, William Garrett, Tak, Paul P., Aggarwal, Charu , Sterman, Daniel H. , Bestvina, Christine M. , Li, Howard Y. , Puri, Sonam , Ibrahim, Omar, Barone, Francesca , Matheny, Christopher Jon

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: TPS9162-TPS9162

10.1200/jco.2023.41.16_suppl.tps9162 Get It

TPS9162 Background: Immune checkpoint inhibitors (ICI) are a standard of care (SOC) treatment that have improved outcomes for patients (pts) with non-small cell lung cancer (NSCLC). However, most pts progress, signaling a need for combination approaches to further improve outcomes. CAN-2409 is a replication-defective adenoviral construct encoding the herpes simplex virus thymidine kinase (HSV-tk) gene that is injected intratumorally followed by 2 weeks of prodrug (valacyclovir or acyclovir). HSV-tk converts the prodrug in the tumor microenvironment into a toxic metabolite, resulting in immunogenic cell death, while the adenoviral proteins provide a strong pro-inflammatory signal. Together, this leads to in situ vaccination against the patient’s own tumor. As a result, CD8+ cytotoxic T cells are educated on how to recognize and kill tumor cells in both the injected tumor and the uninjected metastases. A completed neoadjuvant phase I trial in resectable NSCLC demonstrated safety and immune stimulation (Predina et al 2021), warranting further investigation of CAN-2409 + prodrug as a therapy that can lead to improved long-term outcomes for pts with NSCLC who have a suboptimal response to ICI. Methods: LuTK02 (NCT04495153) is an open-label, multi-arm, phase II clinical trial to evaluate CAN-2409 + prodrug added to SOC ICI (anti-PD-(L)1) therapy in pts with stage III/IV NSCLC presenting with inadequate response (as defined below) to ICI. Cohort 1 includes pts with nonresponding but stable disease ≥18 weeks after starting ICI; cohort 2 includes pts with progressive disease ≥18 weeks after starting ICI. Key eligibility criteria include RECIST-evaluable disease; an injectable lesion (via bronchoscopy or US/IR guidance); ability to continue ICI for the treatment period; no change of ICI or prior interruptions of > 4 weeks within 6 months of enrollment; and no focal therapy at > 3 sites of disease within 12 months prior to enrollment. Key exclusion criteria include a history of ICI immune-related adverse events and known alterations in EGFR, ALK, or ROS1. Eligible patients receive 2 injections of CAN-2409 approximately 6 weeks apart followed by prodrug for 14 days. After treatment of ~40 evaluable pts in cohort 2 with two injections of CAN-2409, the protocol has been amended to include a new cohort (n~20) of pts treated with three injections of CAN-2409 approximately 4 weeks apart, each followed by prodrug for 14 days, to further define the optimal therapeutic regimen. Primary endpoints are overall response and/or disease control rate per RECIST 1.1 criteria and safety of CAN-2409 + prodrug. Secondary endpoints include duration of response, PFS, OS, and biomarker studies. Exploratory endpoints include evaluation of effects in non-injected lesions, changes in non-target (per RECIST) lesions, tumor growth trajectory, and viral shedding. Clinical trial information: NCT04495153 .
Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial.
Phillips, Ryan , Proudfoot, James A. , Liu, Yang , Feng, Felix Y. , Simko, Jeff, Pollack, Alan , Patel, Samir , Straza, Michael , Shah, Amit B. , Rodgers, Joseph P., Davicioni, Elai , Spratt, Daniel E. , Den, Robert B. , Rosenthal, Seth A. , Sartor, Oliver , Sweeney, Christopher J. , Attard, Gerhardt , Efstathiou, Jason A. , Sandler, Howard M. , Tran, Phuoc T

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 5094-5094

10.1200/jco.2023.41.16_suppl.5094 Get It

5094 Background: In prior studies, basal vs. luminal differentiation portends differential response to a) androgen suppression (AS) duration for high-risk prostate cancer (PCa) (NRG-GU-TS006) and b) docetaxel chemotherapy (CT) and AS for metastatic hormone-sensitive disease (CHAARTED). In NRG-GU-TS006, basal tumors appeared to benefit the most from longer duration of AS while those with luminal subtype did not whereas, in CHAARTED, luminal subtype had greater benefit from addition of CT. Herein, we examined basal-luminal subtyping to predict differential response to the addition of CT in the setting of high-risk PCa treated with AS and definitive radiotherapy (AS + RT) in NRG/RTOG 0521. Methods: Per pre-specified and approved NCI analysis plan (Navigator #1061), we obtained available NRG biobank biopsy specimens from patients enrolled on the NRG/RTOG 0521 phase III trial, which randomized patients to AS + RT +/- CT. The highest-grade tumors were profiled on clinical-grade whole-transcriptome arrays (Veracyte, San Diego, CA). Basal-luminal subtypes were generated using a 215-gene PCa subtyping classifier (PSC), a second generation PAM50 basal-luminal model. Treatment effects in Luminal Proliferating (LP) and non-LP subtypes were examined with Cox (for overall survival, OS, and metastasis-free survival, MFS) and Fine & Gray (for distant metastasis, DM) multivariable (MVA) models adjusted for age and trial risk stratification, as well as with restricted mean survival times (RMST). Results: Of 183 samples available for analysis (91 from control and 92 from the CT arm), 52 (28%) were classified as LP subtype. Median follow-up for OS was 9.9 years. No significant differences in clinical or pathological variables were observed between LP and non-LP subtypes. In MVA, we did not detect any significant LP subtype-by-CT treatment interaction but observed evidence of non-proportional hazards (Grambsch-Therneau test, p<0.05). In unselected patients, 5- and 10-year RMST difference between the arms was 0.9 (95% CI [-1.5, 3.4], p=0.46) and 5.7 (95% CI [-2.5, 13.9], p=0.17) months of OS. Stratifying by tumor subtype, at 5 years the RMST difference in months was 3.8 (95% CI [0.3, 7.2], p=0.03) for LP and -0.2 ([-3.4, 2.9], p=0.89) for non-LP. The RMST difference in months at 10-years was 13.7 (95% CI [-0.2, 27.5], p=0.053) for LP and 2.5 ([-7.6, 12.5], p=0.63) for non-LP. Conclusions: In pre-treatment biopsy samples from a Phase 3 trial cohort of localized high-risk men, luminal-basal subtyping of tumors demonstrated differential response to docetaxel CT. Similar to results from the CHAARTED trial of metastatic disease, LP tumors may derive greater benefit from addition of CT. Validation of these findings may enable effective earlier use of CT in men with PCa.
Phase 1 first-in-human study of PF-07257876, a novel CD47/PD-L1 bispecific checkpoint inhibitor, in patients with PD-1/PD-L1-refractory and -naïve advanced solid tumors.
Carneiro, Benedito A. , Safran, Howard , Hamid, Omid , Savvides, Panos, Gutierrez, Martin , Zhao, Yujie , Abbruzzese, James L. , Weroha, Saravut J., Harris, Loleta D., Kent, Sean , Pierceall, William E., Skoura, Athanasia, Zheng, Jenny, Kern, Kenneth A. , Santana-Dávila, Rafael , Beck, J. Thaddeus , Spira, Alexander I. , Savvides, Panos, Ward, Jeffrey P. , Thomas, Jacob Stephen

Mayo Clinic

Journal of Clinical Oncology | June 4, 2023 | Volume: 41 | Issue: 16_suppl | Pages: 2529-2529

10.1200/jco.2023.41.16_suppl.2529 Get It

2529 Background: Tumor expression of the antiphagocytic protein CD47 (integrin associated protein) may lead to immunotherapy resistance (IO-R). PF-07257876 is a novel, IgG1, Fc-active, bispecific antibody targeting CD47 and PD-L1 designed to reverse IO-R, decrease anemia risk, and eliminate a priming dose. We report a Phase 1 dose escalation study (NCT04881045) in patients (pts) with advanced solid tumors, both IO-refractory and IO-naïve. Methods: The study enrolled pts ≥18 yrs with advanced non–small-cell lung carcinoma (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN) with PD-L1 expression >1% post anti-PD-1/PD-L1 therapy. Pts with other PD-L1+ tumors known to express CD47 were included (prior IO not required). Pts received PF-07257876 at escalating dose levels in 28-day cycles. Primary objectives were safety (dose-limiting toxicity [DLT] rate), tolerability, and determination of Recommended Phase 2 Dose (RP2D). Secondary and exploratory objectives included pharmacokinetics (PK), blood receptor occupancy (RO), CD47 levels by immunohistochemistry (IHC), tissue biopsy findings, and objective response rate (ORR) per RECIST v.1.1. Results: As of 20OCT2022, 18 pts were enrolled (NSCLC: n = 6; SCCHN: n = 4; other: n = 8). Median (range) age 68 (46–79) yrs. PF-07257876 was given at ascending doses, 150-2400 mg by subcutaneous (SC) injection or SC infusion every 2 weeks. 16 (89%) pts had treatment-related adverse events (TRAEs): Grades 1/2: n = 12 (67%); Grade 3: n = 1 (6%); Grade 4: n = 3 (17%); no Grade 5. Most common TRAEs: injection site reaction/erythema (n = 13, 72%), thrombocytopenia (n = 6, 33%), anemia (n = 5, 28%), and nausea (n = 4, 22%). DLTs occurred in 2 of 3 pts at the highest tested dose (Grade 4 neutropenia and thrombocytopenia, n = 1; Grade 4 thrombocytopenia, n = 1; both pts recovered). One pt with IO-R SCCHN had a confirmed partial response (duration of response 16 wks). ORR was 5.6% (1/18). Drug exposure increase after 1st dose was not dose proportional. Blood RO was > 95% for PD-L1 and > 70% for CD47 with drug exposure. All pts’ baseline CD47 IHC levels were moderate to high. Pharmacodynamics cytokine profiling showed notable dose-response increases of IFNg, TNFa, CXCL9/10, CCL3/4, without IL-6 increase. Conclusions: PF-07257876 was well tolerated with manageable toxicity. Incidence and grade of anemia or thrombocytopenia were manageable. Target engagement of CD47 and PD-L1 in peripheral blood was high. Innate and adaptive cytokine modulation was observed. Antitumor activity was modest. Expansion is ongoing at 1800 mg. Clinical trial information: NCT04881045 .
Rare variants in ANO1 , encoding a calcium-activated chloride channel, predispose to moyamoya disease
Pinard, Amélie , Ye, Wenlei , Fraser, Stuart , Rosenfeld, Jill A. , Pichurin, Pavel N. , Hickey, Scott E. , Guo, Dongchuan , Cecchi, Alana C. , Boerio, Maura L. , Guey, Stéphanie , Aloui, Chaker , Alyemni, Saleh, Bamshad, Michael J. , Nickerson, Deborah A. , Jin, Sheng Chih , Smith, Edward R. , Haider, Shozeb , Jin, Sheng Chih , Milewicz, Dianna M , Rosenfield, Jill A , Guey, Stéphanie , Smith, Edward , Lee, Kwanghyuk , Kraemer, Markus , Tournier‐Lasserve, Elisabeth , Haider, Shozeb , Kahle, Kristopher T. , Jan, Lily Yeh , He, Mu , Milewicz, Dianna M.

Mayo Clinic

Brain | May 24, 2023 | Volume: 146 | Issue: 9 | Pages: 3616-3623

10.1093/brain/awad172 | PMID 37253099 Get It

Abstract Moyamoya disease, a cerebrovascular disease leading to strokes in children and young adults, is characterized by progressive occlusion of the distal internal carotid arteries and the formation of collateral vessels. Altered genes play a prominent role in the aetiology of moyamoya disease, but a causative gene is not identified in the majority of cases. Exome sequencing data from 151 individuals from 84 unsolved families were analysed to identify further genes for moyamoya disease, then candidate genes assessed in additional cases (150 probands). Two families had the same rare variant in ANO1, which encodes a calcium-activated chloride channel, anoctamin-1. Haplotype analyses found the families were related, and ANO1 p.Met658Val segregated with moyamoya disease in the family with an LOD score of 3.3. Six additional ANO1 rare variants were identified in moyamoya disease families. The ANO1 rare variants were assessed using patch-clamp recordings, and the majority of variants, including ANO1 p.Met658Val, displayed increased sensitivity to intracellular Ca2+. Patients harbouring these gain-of-function ANO1 variants had classic features of moyamoya disease, but also had aneurysm, stenosis and/or occlusion in the posterior circulation. Our studies support that ANO1 gain-of-function pathogenic variants predispose to moyamoya disease and are associated with unique involvement of the posterior circulation.
Going Flat: Mastectomy without Breast Reconstruction
Kandi, Lyndsay A. , Movtchan, Nellie V., Hostler, Andrew C. , Howard, Michael A., Teven, Chad M.

Mayo Clinic

Plastic & Reconstructive Surgery | May 24, 2023 | Volume: 152 | Issue: 3 | Pages: 553e-554e

10.1097/prs.0000000000010544 | PMID 37224411 Get It

Interim Results of a Phase 1/2 Open‐Label Study of INO ‐3107 for HPV ‐6 and/or
Mau, Ted , Belafsky, Peter C. , Best, Simon R. , Friedman, Aaron D. , Lott, David G. , Paniello, Randal C. , Pransky, Seth M. , Howard, Tamara , Dallas, Michael, Patel, Aditya , Morrow, Matthew P. , Skolnik, Jeffrey M. , Best, Simon R , Friedman, Aaron D , Lott, David G , Paniello, Randal C , Mau, Ted , Amin, Milan R , Klein, Adam M. , Saba, Nabil F. , Howard, Tamara, Dallas, Michael J.

Mayo Clinic

The Laryngoscope | May 19, 2023 | Volume: 133 | Issue: 11 | Pages: 3087-3093

10.1002/lary.30749 | PMID 37204106 Get It

Objective To evaluate the safety, immunogenicity, and efficacy of INO‐3107, a DNA immunotherapy designed to elicit targeted T‐cell responses against human papillomavirus (HPV) types 6 and 11, in adult patients with recurrent respiratory papillomatosis (RRP; NCT04398433). Methods Eligible patients required ≥2 surgical interventions for RRP in the year preceding dosing. INO‐3107 was administered by intramuscular (IM) injection followed by electroporation (EP) on weeks 0, 3, 6, and 9. Patients underwent surgical debulking within 14 days prior to first dose, with office laryngoscopy and staging at screening and weeks 6, 11, 26, and 52. Primary endpoint was safety and tolerability, as assessed by treatment‐emergent adverse events (TEAEs). Secondary endpoints included frequency of surgical interventions post‐INO‐3107 and cellular immune responses. Results An initial cohort of 21 patients was enrolled between October 2020 and August 2021. Fifteen (71.4%) patients had ≥1 TEAE; 11 (52.4%) were Grade 1, and 3 (14.3%) were Grade 3 (none treatment related). The most frequently reported TEAE was injection site or procedural pain ( n = 8; 38.1%). Sixteen (76.2%) patients had fewer surgical interventions in the year following INO‐3107 administration, with a median decrease of 3 interventions versus the preceding year. The RRP severity score, modified by Pransky, showed improvement from baseline to week 52. INO‐3107 induced durable cellular responses against HPV‐6 and HPV‐11, with an increase in activated CD4 and CD8 T cells and CD8 cells with lytic potential. Conclusion The data suggest that INO‐3107 administered by IM/EP is tolerable and immunogenic and provides clinical benefit to adults with RRP. Level of Evidence 3 Laryngoscope , 133:3087–3093, 2023
Proteomic and Clinicopathologic Assessment of Penile Amyloidosis: A Single Institutional Review of 12 Cases
Gilani, Sarwat, Dasari, Surendra , Theis, Jason D. , Dao, Linda N. , Cubilla, Antonio L. , Hernandez, Loren P. Herrera , Jiménez, Rafael E. , Cheville, John C. , Howard, Matthew T., Guo, Ruifeng , Gupta, Sounak , Gilani, Sarwat I, Herrera Hernandez, Loren P, Guo, Ruifeng , Tekin, Burak , Rech, Karen L. , Dispenzieri, Angela , McPhail, Ellen Darcy , Erickson, Lori A

Mayo Clinic

American Journal of Clinical Pathology | May 19, 2023 | Volume: 160 | Issue: 3 | Pages: 303-313

10.1093/ajcp/aqad054 | PMID 37203248 Get It

Abstract Objectives There is a paucity of data on penile amyloidosis. We aimed to assess the frequency of different amyloid types in surgical specimens from the penis involved by amyloidosis and correlate relevant clinicopathologic parameters with proteomic findings. Methods Since 2008, our reference laboratory has performed liquid chromatography/tandem mass spectrometry (LC-MS/MS) for amyloid typing. The institutional pathology archive and reference laboratory database were queried to retrospectively identify all penile surgical pathology specimens with LC-MS/MS results between January 1, 2008, and November 23, 2022. Archived H&E-stained and Congo red–stained sections were re-reviewed. Results Twelve cases of penile amyloidosis were identified, which represented 0.35% (n = 3,456) of penile surgical specimens. AL-type amyloid was most frequent (n = 7), followed by keratin-type amyloid (n = 3) and ATTR (transthyretin)–type amyloid (n = 2). AL-type amyloid cases often showed diffuse dermal/lamina propria deposition, whereas all keratin-type amyloid cases were localized to the superficial dermis. Two cases with keratin-type amyloid had concomitant cutaneous findings (penile intraepithelial neoplasia and condyloma). Conclusions This series, the largest to date, demonstrates that penile amyloidosis has a heterogeneous proteomic landscape. To the best of our knowledge, this is the first study describing ATTR (transthyretin)–type penile amyloid.
Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research
Taylor, Jack C. , Heuer, Hilary W. , Clark, Annie L , Wise, Amy B. , Manoochehri, Masood , Forsberg, Leah K. , Mester, Carly , Rao, Meghana , Brushaber, Daniell, Kramer, Joel H. , Welch, Ariane E., Kornak, John , Kremers, Walter K. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Hall, Matthew , Huey, Edward D. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Rankin, Katherine P. , Ratnasiri, Buddhika , Wong, Bonnie , Gorno‐Tempini, Maria Luisa , Rosen, Howard J. , Boxer, Adam L. , Staffaroni, Adam M. , Taylor, Jack Carson , Staffaroni, Adam M , Pascual, Belen , Kremers, Walter K , Domoto-Reilly, Kimiko , Brushaber, Danielle , Appleby, Brian S. , Dickerson, Bradford Clark , Grossman, Murray , Irwin, David J. , Lapid, Maria I. , Litvan, Irene , Masdeu, Joseph C , Nevler, Naomi , Rojas, Julio C. , Tartaglia, Maria Carmela , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring | May 10, 2023 | Volume: 15 | Issue: 2 | Pages: No page available

10.1002/dad2.12423 | PMID 37180971 Get It

AbstractIntroductionRemote smartphone assessments of cognition, speech/language, and motor functioning in frontotemporal dementia (FTD) could enable decentralized clinical trials and improve access to research. We studied the feasibility and acceptability of remote smartphone data collection in FTD research using the ALLFTD Mobile App (ALLFTD‐mApp).MethodsA diagnostically mixed sample of 214 participants with FTD or from familial FTD kindreds (asymptomatic: CDR®+NACC‐FTLD = 0 [N = 101]; prodromal: 0.5 [N = 49]; symptomatic ≥1 [N = 51]; not measured [N = 13]) were asked to complete ALLFTD‐mApp tests on their smartphone three times within 12 days. They completed smartphone familiarity and participation experience surveys.ResultsIt was feasible for participants to complete the ALLFTD‐mApp on their own smartphones. Participants reported high smartphone familiarity, completed ∼ 70% of tasks, and considered the time commitment acceptable (98% of respondents). Greater disease severity was associated with poorer performance across several tests.DiscussionThese findings suggest that the ALLFTD‐mApp study protocol is feasible and acceptable for remote FTD research.HIGHLIGHTS The ALLFTD Mobile App is a smartphone‐based platform for remote, self‐administered data collection. The ALLFTD Mobile App consists of a comprehensive battery of surveys and tests of executive functioning, memory, speech and language, and motor abilities. Remote digital data collection using the ALLFTD Mobile App was feasible in a multicenter research consortium that studies FTD. Data was collected in healthy controls and participants with a range of diagnoses, particularly FTD spectrum disorders. Remote digital data collection was well accepted by participants with a variety of diagnoses.
Melanoma: Does It Present Differently in Darker Skin Tones?
Thompson, Brandon, Jenkins, Toni, Sanchez, J. , Frederick, Matthew, Posligua-Alban, Alba, Barbosa, Naiara S. , Sánchez, John Paul , Barbosa, Naiara Sbroggio, Thompson, Brandon

Mayo Clinic

MedEdPORTAL | May 9, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11311 | PMID 37181454 Get It

Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH): Results From the Phase 2 TORREY Trial
McLaughlin, V.V., Zolty, Ronald , Channick, Richard N. , Chin, K. , Vachiéry, Jean‐Luc , Zamanian, R.T., Cravets, Matt , Roscigno, R.F., Mottola, David, Elman, Erin, Parsley, E., Aranda, R., Zisman, Lawrence S. , Investigators, on behalf of the TORREY Study, Frantz, Robert P. , Sahay, Sandeep , Subías, Pilar Escribano , Benza, Raymond L. , Channick, Richard N. , Hemnes, Anna R. , Howard, Luke , Sitbon, Olivier , Ghofrani, Hossein Ardeschir

Mayo Clinic

D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6726-A6726

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6726 Get It